Avanir, Otsuka Pharmaceutical deal

Otsuka is acquiring Avanir for $17 per share in a deal valued at about $3.5 billion. The price represents a 13% premium to Avanir’s closing price of $15 on Dec. 1, before the deal was announced. The deal is expected to close in 1Q15. ...